Mid‐dose mifepristone (25 mg‐50 mg) leads to lower observed number of pregnancies (all women) compared with low‐dose mifepristone (< 25 mg) (high certainty).
Mid‐dose mifepristone (25 mg‐50 mg) probably leads to higher any side effect compared with low‐dose mifepristone (< 25 mg) (moderate certainty).
Mid‐dose mifepristone (25 mg‐50 mg) showed no clear difference in specific side effects ‐ nausea compared with low‐dose mifepristone (< 25 mg) (moderate certainty).
Mid‐dose mifepristone (25 mg‐50 mg) showed no clear difference in specific side effects ‐ vomiting compared with low‐dose mifepristone (< 25 mg) (moderate certainty).
Mid‐dose mifepristone (25 mg‐50 mg) leads to higher specific side effects ‐ spotting/bleeding after treatment compared with low‐dose mifepristone (< 25 mg) (high certainty).
Mid‐dose mifepristone (25 mg‐50 mg) showed no clear difference in menses ‐ early compared with low‐dose mifepristone (< 25 mg) (low certainty).
Mid‐dose mifepristone (25 mg‐50 mg) probably leads to higher menses ‐ delay compared with low‐dose mifepristone (< 25 mg) (moderate certainty).
Mid‐dose mifepristone (25 mg‐50 mg) showed no clear difference in specific side effect ‐ nausea compared with levonorgestrel 1.5 mg (low certainty).
The review found no eligible studies for this question.
Mid‐dose mifepristone (25 mg‐50 mg) may leads to lower specific side effect ‐ spotting/bleeding after treatment compared with levonorgestrel 1.5 mg (low certainty).
Mid‐dose mifepristone (25 mg‐50 mg) showed no clear difference in menses ‐ early compared with levonorgestrel 1.5 mg (low certainty).
Mid‐dose mifepristone (25 mg‐50 mg) probably leads to higher menses ‐ delay compared with levonorgestrel 1.5 mg (moderate certainty).
Mid‐dose mifepristone (25 mg‐50 mg) probably leads to lower observed number of pregnancies (all women) compared with levonorgestrel 1.5 mg (moderate certainty).
Mid‐dose mifepristone (25 mg‐50 mg) may leads to lower any side effect compared with levonorgestrel 1.5 mg (low certainty).